The race between covid-19 vaccines and variants is on. Alok Jha, The Economist’s science correspondent, and Natasha Loder, health policy editor, discuss what this means for the future Read more of our coverage on coronavirus: https://econ.st/3t1L6wx
The coronavirus’s Delta variant accounts for ever more infections; we ask about mutational surprises yet to emerge, and what can be done about them.
The ousting of Ethiopia’s army from the Tigray region might precipitate far wider conflict—within the country and far beyond its borders. And ahead of the Fourth of July, we find no good films about the holiday.
A.M. Edition for June 30. WSJ Africa Deputy Bureau Chief Gabriele Steinhauser on how the region is dealing with a surge of the more-transmissible Delta variant.
Chinese ride-hailing giant Didi is set to begin trading today in the U.S. And, differing stances on vaccine passports. Marc Stewart hosts.
India’s Covid-19 crisis has resulted in record numbers of cases and deaths. WSJ breaks down the chain of events that led to the fastest-growing wave of infection since the pandemic started, and what it means for the world. Photo: Samuel Rajkumar/Reuters
The virus that causes COVID-19 is mutating. Here is what you should know if you want to understand how variants are (and aren’t) complicating the pandemic.
Learn more at: https://gatesnot.es/3sP668R.SHOW LESS
An aggressive Covid-19 variant called P.1 has spread from the Amazon to other parts of Brazil and has now been identified in U.S. cases. WSJ’s Paulo Trevisani reports from Porto Alegre’s overwhelmed hospitals, where doctors say young people are getting ill. Photo: Tommaso Protti for The Wall Street Journal
As highly transmissible coronavirus variants sweep across the world, scientists are racing to understand why these new versions of the virus are spreading faster, and what this could mean for vaccine efforts. New research says the key may be the spike protein, which gives the coronavirus its unmistakable shape. Illustration: Nick Collingwood/WSJ
Just two months ago, the incredible performance of new vaccines from Moderna and Pfizer had people cheering for an imminent end to the pandemic. But an onslaught of fast-spreading and potentially dangerous mutations of the virus changed that.
So now, even as pharma companies ramp up production in the early stages of a massive rollout, they are racing to retool their vaccine strategies. Robert Langreth reports that booster shots could give drugmakers a lucrative new revenue stream.
The second impeachment trial of former President Donald Trump begins this week as Republicans and his legal team argue the impeachment is unconstitutional.
And, South Africa has paused a planned deployment of a coronavirus vaccine from AstraZeneca after a study there showed it may be less effective against a new strain of the virus detected there. Also, how worried are U.S. health officials about variant strains of the virus in the U.S.?